Boston Scientific (NYSE:BSX) said it plans to immediately launch its Promus Premier drug-eluting stent across the pond, now that the European Union has given the device CE Mark approval.
The Natick, Mass.-based medical device company touts the device as the sole entrant in the DES market to feature a platinum-chromium chassis, an everolimus coating and "an enhanced stent delivery system," according to a press release.*
"The Promus Premier stent system is the latest example of our unparalleled pipeline of drug-eluting stent technologies and reflects our commitment to global DES market leadership," Boston Scientific’s interventional cardiology president Kevin Ballinger said in prepared remarks. "We are proud that our research, clinical, regulatory and manufacturing teams delivered the next advance in stent technology in an expedited time."
Boston Scientific said it’s already starting its market push in Europe for the Promus Premier stent.
*Correction, Feb. 13, 2013: This article originally referred to Boston Scientific’s headquarters as being in Marlborough, Mass. Although the company is moving its base from Natick, Mass., to Marlborough, that shift is not expected to be complete until the summer of 2014, spokesman Steve Campanini told MassDevice.com.
Return to the corrected sentence.